4CPS-005 GLP-1 agonist liraglutide as add-on therapy in type 2 diabetes
BackgroundPurposeThe aim of this study was to evaluate the real-world efficacy and safety of adding Liraglutide in inadequately controlled patients with oral antidiabetic drugs.Material and methodsThis observational study assessed the efficacy and safety of GLP-1 agonist Liraglutide used as add-on t...
Gespeichert in:
| Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A69-A70 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A70 |
|---|---|
| container_issue | Suppl 1 |
| container_start_page | A69 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 26 |
| creator | Blánquez Martínez, D Hayon Ponce, M Casas Hidalgo, I Diaz Villamarin, X Raquel, ÁS Nieto Gómez, P Davila Fajardo, C |
| description | BackgroundPurposeThe aim of this study was to evaluate the real-world efficacy and safety of adding Liraglutide in inadequately controlled patients with oral antidiabetic drugs.Material and methodsThis observational study assessed the efficacy and safety of GLP-1 agonist Liraglutide used as add-on therapy in a group of 83 type 2 diabetes (T2DM) patients from a community endocrinology practice in a 6 month period (July to September 2017). We have retrospectively analysed epidemiological, anthropometric and laboratory data. The primary endpoint was changes in glycated haemoglobin (HbA1C) and secondary endpoints included changes in body mass index (BMI), blood pressure (BP), biochemical parameters and percentage of patients reporting adverse effects of therapy.Data were analysed using SPSS version 20.0 and comparisons of continuous variables were performed using Student’s t test.ResultsEighty-three patients were included (54.2% male). Mean age 56.76±9.87 years, mean duration of T2DM 9.46±5.46 years. Prior to treatment, patients had BMI 37.68±6.82 Kg/m2, systolic BP (SBP) 138.80±15.46 mmHg, diastolic BP (DBP) 82.87±10.16 mmHg, fasting glucose 187.33±55.11 mg/dL, HbA1C 8.62%±1.3%, total cholesterol 178.1±35.74 mg/dL, LDL cholesterol (c-LDL) 97.66±32.16 mg/dL, HDL cholesterol (c-HDL) 44.54±13.78 mg/dL, triglycerides 197.64±24.19 mg/dL, GOT 29±20.311 U/L and GPT 39.88±31.69 U/L.Clinical and biochemical values at 6 months were: BMI 36.08±6.32 Kg/m2 (p |
| doi_str_mv | 10.1136/ejhpharm-2019-eahpconf.154 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2190010072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2190010072</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1264-966b655687ba8f9713bfd1c3ada0efd992850dde58d7641abed42cebe80c54703</originalsourceid><addsrcrecordid>eNo90M1KAzEUBeAgCpbadwi6Tr35nclSitZCwYK6Dskk05nSzozJdNGdG1_UJ-mUWlf3LA7nwofQPYUppVw9hk3VVTbuCAOqSbBVV7RNOaVSXKERA5ERrZW4_s9S3aJJSrUDyXmuBdcjtBCz1TsBkL_fP_PlilBs121Tpx5v62jX231f-4BtwtZ70ja4r0K03QHXQzx0ATPsa-tCH9IduintNoXJ3x2jz5fnj9krWb7NF7OnJXGUKUG0Uk5JqfLM2bzUGeWu9LTg1lsIpdea5RK8DzL3mRJ02PaCFcGFHAopMuBj9HDe7WL7tQ-pN5t2H5vhpWFUA1CAjA0teW653cZ0sd7ZeDAUzAnOXODMCc5c4MwAx4_AMWVU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2190010072</pqid></control><display><type>article</type><title>4CPS-005 GLP-1 agonist liraglutide as add-on therapy in type 2 diabetes</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Blánquez Martínez, D ; Hayon Ponce, M ; Casas Hidalgo, I ; Diaz Villamarin, X ; Raquel, ÁS ; Nieto Gómez, P ; Davila Fajardo, C</creator><creatorcontrib>Blánquez Martínez, D ; Hayon Ponce, M ; Casas Hidalgo, I ; Diaz Villamarin, X ; Raquel, ÁS ; Nieto Gómez, P ; Davila Fajardo, C</creatorcontrib><description>BackgroundPurposeThe aim of this study was to evaluate the real-world efficacy and safety of adding Liraglutide in inadequately controlled patients with oral antidiabetic drugs.Material and methodsThis observational study assessed the efficacy and safety of GLP-1 agonist Liraglutide used as add-on therapy in a group of 83 type 2 diabetes (T2DM) patients from a community endocrinology practice in a 6 month period (July to September 2017). We have retrospectively analysed epidemiological, anthropometric and laboratory data. The primary endpoint was changes in glycated haemoglobin (HbA1C) and secondary endpoints included changes in body mass index (BMI), blood pressure (BP), biochemical parameters and percentage of patients reporting adverse effects of therapy.Data were analysed using SPSS version 20.0 and comparisons of continuous variables were performed using Student’s t test.ResultsEighty-three patients were included (54.2% male). Mean age 56.76±9.87 years, mean duration of T2DM 9.46±5.46 years. Prior to treatment, patients had BMI 37.68±6.82 Kg/m2, systolic BP (SBP) 138.80±15.46 mmHg, diastolic BP (DBP) 82.87±10.16 mmHg, fasting glucose 187.33±55.11 mg/dL, HbA1C 8.62%±1.3%, total cholesterol 178.1±35.74 mg/dL, LDL cholesterol (c-LDL) 97.66±32.16 mg/dL, HDL cholesterol (c-HDL) 44.54±13.78 mg/dL, triglycerides 197.64±24.19 mg/dL, GOT 29±20.311 U/L and GPT 39.88±31.69 U/L.Clinical and biochemical values at 6 months were: BMI 36.08±6.32 Kg/m2 (p<0.001), SBP 132.76±12.11 mmHg (p<0.001), DBP 77.41±5.62 mmHg (p<0.000), fasting glucose 165.16±56 mg/dL (p=0.003), HbA1C 7.73%±1.33% (p<0.001), total cholesterol 170.6±39.19 mg/dL (p=0.230), c-HDL 46.25±15.03 mg/dL (p=0.151), c-LDL 87.74±30.5 mg/dL (p=0.007), triglycerides 198.29±22.29 mg/dL (p=0.957), GOT 24.97±12.49 U/L (p=0.051) and GPT 32.76±18.24 U/L (p=0.026). Any adverse effect was reported.Statistically significant differences were found regarding several variables, such as BMI, HbA1C, fasting glucose, blood pressure, c-LDL and GPT. No differences were found in total cholesterol, c-HDL, triglycerides and GOT.ConclusionSix-month therapy with Liraglutide improves not only glycemic control (HbA1C, fasting glucose) but also cardiovascular risk factors (BMI, BP, c-LDL), reducing SBP and DBP by 1 to 5 mmHg. Therefore, Liraglutide may offer an alternative therapy for these patients and will help provide extra cardiovascular benefits.References and/or acknowledgementsNo conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2019-eahpconf.154</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Antidiabetics ; Blood pressure ; Body mass index ; Cholesterol ; Diabetes ; Fasting ; Triglycerides</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A69-A70</ispartof><rights>2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2019 2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Blánquez Martínez, D</creatorcontrib><creatorcontrib>Hayon Ponce, M</creatorcontrib><creatorcontrib>Casas Hidalgo, I</creatorcontrib><creatorcontrib>Diaz Villamarin, X</creatorcontrib><creatorcontrib>Raquel, ÁS</creatorcontrib><creatorcontrib>Nieto Gómez, P</creatorcontrib><creatorcontrib>Davila Fajardo, C</creatorcontrib><title>4CPS-005 GLP-1 agonist liraglutide as add-on therapy in type 2 diabetes</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundPurposeThe aim of this study was to evaluate the real-world efficacy and safety of adding Liraglutide in inadequately controlled patients with oral antidiabetic drugs.Material and methodsThis observational study assessed the efficacy and safety of GLP-1 agonist Liraglutide used as add-on therapy in a group of 83 type 2 diabetes (T2DM) patients from a community endocrinology practice in a 6 month period (July to September 2017). We have retrospectively analysed epidemiological, anthropometric and laboratory data. The primary endpoint was changes in glycated haemoglobin (HbA1C) and secondary endpoints included changes in body mass index (BMI), blood pressure (BP), biochemical parameters and percentage of patients reporting adverse effects of therapy.Data were analysed using SPSS version 20.0 and comparisons of continuous variables were performed using Student’s t test.ResultsEighty-three patients were included (54.2% male). Mean age 56.76±9.87 years, mean duration of T2DM 9.46±5.46 years. Prior to treatment, patients had BMI 37.68±6.82 Kg/m2, systolic BP (SBP) 138.80±15.46 mmHg, diastolic BP (DBP) 82.87±10.16 mmHg, fasting glucose 187.33±55.11 mg/dL, HbA1C 8.62%±1.3%, total cholesterol 178.1±35.74 mg/dL, LDL cholesterol (c-LDL) 97.66±32.16 mg/dL, HDL cholesterol (c-HDL) 44.54±13.78 mg/dL, triglycerides 197.64±24.19 mg/dL, GOT 29±20.311 U/L and GPT 39.88±31.69 U/L.Clinical and biochemical values at 6 months were: BMI 36.08±6.32 Kg/m2 (p<0.001), SBP 132.76±12.11 mmHg (p<0.001), DBP 77.41±5.62 mmHg (p<0.000), fasting glucose 165.16±56 mg/dL (p=0.003), HbA1C 7.73%±1.33% (p<0.001), total cholesterol 170.6±39.19 mg/dL (p=0.230), c-HDL 46.25±15.03 mg/dL (p=0.151), c-LDL 87.74±30.5 mg/dL (p=0.007), triglycerides 198.29±22.29 mg/dL (p=0.957), GOT 24.97±12.49 U/L (p=0.051) and GPT 32.76±18.24 U/L (p=0.026). Any adverse effect was reported.Statistically significant differences were found regarding several variables, such as BMI, HbA1C, fasting glucose, blood pressure, c-LDL and GPT. No differences were found in total cholesterol, c-HDL, triglycerides and GOT.ConclusionSix-month therapy with Liraglutide improves not only glycemic control (HbA1C, fasting glucose) but also cardiovascular risk factors (BMI, BP, c-LDL), reducing SBP and DBP by 1 to 5 mmHg. Therefore, Liraglutide may offer an alternative therapy for these patients and will help provide extra cardiovascular benefits.References and/or acknowledgementsNo conflict of interest.</description><subject>Antidiabetics</subject><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Cholesterol</subject><subject>Diabetes</subject><subject>Fasting</subject><subject>Triglycerides</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo90M1KAzEUBeAgCpbadwi6Tr35nclSitZCwYK6Dskk05nSzozJdNGdG1_UJ-mUWlf3LA7nwofQPYUppVw9hk3VVTbuCAOqSbBVV7RNOaVSXKERA5ERrZW4_s9S3aJJSrUDyXmuBdcjtBCz1TsBkL_fP_PlilBs121Tpx5v62jX231f-4BtwtZ70ja4r0K03QHXQzx0ATPsa-tCH9IduintNoXJ3x2jz5fnj9krWb7NF7OnJXGUKUG0Uk5JqfLM2bzUGeWu9LTg1lsIpdea5RK8DzL3mRJ02PaCFcGFHAopMuBj9HDe7WL7tQ-pN5t2H5vhpWFUA1CAjA0teW653cZ0sd7ZeDAUzAnOXODMCc5c4MwAx4_AMWVU</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Blánquez Martínez, D</creator><creator>Hayon Ponce, M</creator><creator>Casas Hidalgo, I</creator><creator>Diaz Villamarin, X</creator><creator>Raquel, ÁS</creator><creator>Nieto Gómez, P</creator><creator>Davila Fajardo, C</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201903</creationdate><title>4CPS-005 GLP-1 agonist liraglutide as add-on therapy in type 2 diabetes</title><author>Blánquez Martínez, D ; Hayon Ponce, M ; Casas Hidalgo, I ; Diaz Villamarin, X ; Raquel, ÁS ; Nieto Gómez, P ; Davila Fajardo, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1264-966b655687ba8f9713bfd1c3ada0efd992850dde58d7641abed42cebe80c54703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antidiabetics</topic><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Cholesterol</topic><topic>Diabetes</topic><topic>Fasting</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blánquez Martínez, D</creatorcontrib><creatorcontrib>Hayon Ponce, M</creatorcontrib><creatorcontrib>Casas Hidalgo, I</creatorcontrib><creatorcontrib>Diaz Villamarin, X</creatorcontrib><creatorcontrib>Raquel, ÁS</creatorcontrib><creatorcontrib>Nieto Gómez, P</creatorcontrib><creatorcontrib>Davila Fajardo, C</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blánquez Martínez, D</au><au>Hayon Ponce, M</au><au>Casas Hidalgo, I</au><au>Diaz Villamarin, X</au><au>Raquel, ÁS</au><au>Nieto Gómez, P</au><au>Davila Fajardo, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4CPS-005 GLP-1 agonist liraglutide as add-on therapy in type 2 diabetes</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2019-03</date><risdate>2019</risdate><volume>26</volume><issue>Suppl 1</issue><spage>A69</spage><epage>A70</epage><pages>A69-A70</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundPurposeThe aim of this study was to evaluate the real-world efficacy and safety of adding Liraglutide in inadequately controlled patients with oral antidiabetic drugs.Material and methodsThis observational study assessed the efficacy and safety of GLP-1 agonist Liraglutide used as add-on therapy in a group of 83 type 2 diabetes (T2DM) patients from a community endocrinology practice in a 6 month period (July to September 2017). We have retrospectively analysed epidemiological, anthropometric and laboratory data. The primary endpoint was changes in glycated haemoglobin (HbA1C) and secondary endpoints included changes in body mass index (BMI), blood pressure (BP), biochemical parameters and percentage of patients reporting adverse effects of therapy.Data were analysed using SPSS version 20.0 and comparisons of continuous variables were performed using Student’s t test.ResultsEighty-three patients were included (54.2% male). Mean age 56.76±9.87 years, mean duration of T2DM 9.46±5.46 years. Prior to treatment, patients had BMI 37.68±6.82 Kg/m2, systolic BP (SBP) 138.80±15.46 mmHg, diastolic BP (DBP) 82.87±10.16 mmHg, fasting glucose 187.33±55.11 mg/dL, HbA1C 8.62%±1.3%, total cholesterol 178.1±35.74 mg/dL, LDL cholesterol (c-LDL) 97.66±32.16 mg/dL, HDL cholesterol (c-HDL) 44.54±13.78 mg/dL, triglycerides 197.64±24.19 mg/dL, GOT 29±20.311 U/L and GPT 39.88±31.69 U/L.Clinical and biochemical values at 6 months were: BMI 36.08±6.32 Kg/m2 (p<0.001), SBP 132.76±12.11 mmHg (p<0.001), DBP 77.41±5.62 mmHg (p<0.000), fasting glucose 165.16±56 mg/dL (p=0.003), HbA1C 7.73%±1.33% (p<0.001), total cholesterol 170.6±39.19 mg/dL (p=0.230), c-HDL 46.25±15.03 mg/dL (p=0.151), c-LDL 87.74±30.5 mg/dL (p=0.007), triglycerides 198.29±22.29 mg/dL (p=0.957), GOT 24.97±12.49 U/L (p=0.051) and GPT 32.76±18.24 U/L (p=0.026). Any adverse effect was reported.Statistically significant differences were found regarding several variables, such as BMI, HbA1C, fasting glucose, blood pressure, c-LDL and GPT. No differences were found in total cholesterol, c-HDL, triglycerides and GOT.ConclusionSix-month therapy with Liraglutide improves not only glycemic control (HbA1C, fasting glucose) but also cardiovascular risk factors (BMI, BP, c-LDL), reducing SBP and DBP by 1 to 5 mmHg. Therefore, Liraglutide may offer an alternative therapy for these patients and will help provide extra cardiovascular benefits.References and/or acknowledgementsNo conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2019-eahpconf.154</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A69-A70 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_proquest_journals_2190010072 |
| source | PubMed Central; EZB Electronic Journals Library |
| subjects | Antidiabetics Blood pressure Body mass index Cholesterol Diabetes Fasting Triglycerides |
| title | 4CPS-005 GLP-1 agonist liraglutide as add-on therapy in type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T10%3A48%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4CPS-005%E2%80%85GLP-1%20agonist%20liraglutide%20as%20add-on%20therapy%20in%20type%202%20diabetes&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Bl%C3%A1nquez%20Mart%C3%ADnez,%20D&rft.date=2019-03&rft.volume=26&rft.issue=Suppl%201&rft.spage=A69&rft.epage=A70&rft.pages=A69-A70&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2019-eahpconf.154&rft_dat=%3Cproquest_bmj_p%3E2190010072%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2190010072&rft_id=info:pmid/&rfr_iscdi=true |